Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.
Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.
Pfizer reports positive BREAKWATER data for BRAFTOVI in BRAF-mutant mCRC. Find out what this could change for frontline colorectal cancer care.
FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.
FDA accepts tirabrutinib NDA for relapsed or refractory PCNSL. Find out what this means for CNS lymphoma treatment and regulatory strategy.
Twist Bioscience licenses Invenra’s bispecific antibody platform. Find out how this reshapes biologics discovery infrastructure and industry dynamics.
Janux Therapeutics begins first human study of JANX011. Find out how CD19 immune reset could change autoimmune treatment strategies.
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.
EU approves 7.2 mg Wegovy for obesity. Explore what this means for efficacy, competition and reimbursement across Europe.